The Safety, Tolerability, Pharmacokinetics, and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b StudyBram Verstockt, Silvio Danese, Séverine Vermeire et al.|Journal of Crohn s and Colitis|2023Cited by 15
P144 Modulation of Immunometabolism via NLRX1 or PLXDC2: Novel Bimodal Mechanisms for the Treatment of Inflammatory Bowel DiseasesSilvio Danese, Bram Verstockt, J F Colombel et al.|Journal of Crohn s and Colitis|2024Cited by 3
P077 The Immunometabolic Bimodal Mechanism of NLRX1 Agonist NX-13 in a Pig Model of Ulcerative ColitisBram Verstockt, Silvio Danese, Rebecca Mosig et al.|Journal of Crohn s and Colitis|2024Cited by 1
P086 Identification of a Novel Immunometabolic Target and Agonist for PLXDC2 for Amelioration of DSS Colitis Model in MiceSaeed Abdurahiman, Bram Verstockt, Rebecca Mosig et al.|Journal of Crohn s and Colitis|2024Cited by 1
P571 The Effect of NLRX1 Activation on Eosinophils in Ulcerative Colitis and Inflammation: Translational Learnings Across Diseases and from Mouse to HumanBram Verstockt, Séverine Vermeire, Marla C. Dubinsky et al.|Journal of Crohn s and Colitis|2024Cited by 1